Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma

Table 1

Death receptor-targeted agents in clinical development.

Agents	Phase	Target Cancer	Current status	Responses	Ref.
Dulanermin	1	Advanced Ca	Completed	2 PR Chondrosarcoma, 46% SD	[41]
Lexatumumab	1	Advanced Ca	Completed	No PR, 32% SD	[42]
Lexatumumab	1	Advanced Ca	Completed	No PR, 29% SD	[43]
Lexatumumab	1	Advanced Ca	Completed	21% SD	[44]
Drozitumab	1	Advanced Ca	Completed	3 minor response, 49% SD	[45]
Drozitumab	2	Chondrosarcoma	Terminated	NA	NA
Conatumumab	1	Advanced Ca	Completed	1 PR NSCLC, 38% SD	[46]
Conatumumab	1	Advanced Ca	Completed	50% SD	[47]
Tigatuzumab	1	Advanced Ca	Completed	41% SD	[48]
				Combination
Dulanermin	1b	NSCLC	Completed	Paclitaxel, carboplatin, and bevacizumab	[49]
Dulanermin	1b	Colon Ca	Recruiting	Camptosar/Erbitux or FOLFIRI	NA
Dulanermin	1b	Colon Ca	Active	FOLFOX, Bevacizumab	NA
Dulanermin	2	NHL	Completed	Rituximab	NA
Lexatumumab	1	Pediatric Ca	Completed	IFNγ	NA
Drozitumab	2	NSCLC	Completed	Paclitaxel, carboplatin, and bevacizumab	NA
Drozitumab	1b	Colon Ca	Completed	lrinotecan, cetuximab, and FOLFIRI with bevacizumab	NA
Drozitumab	1b	Colon Ca	Completed	FOLFOX and Bevacizumab	NA
Drozitumab	2	NHL	Completed	Rituximab	NA
Conatumumab	1b	NHL	Suspended	bortezomib or vorinostat	NA
Conatumumab	1b/2	Colon Ca	Active	mFOLFOX6 and Bevacizumab	NA
Conatumumab	1b/2	Advanced Ca	Active	Anti-IGF1R	NA
Conatumumab	1b/2	NSCLC	Completed	Paclitaxel and carboplatin	NA
Conatumumab	1b/2	Soft tissue sarcoma	Active	Doxorubicin	NA
Conatumumab	1b/2	Pancreatic Ca	Active	gemcitabine	NA
Conatumumab	2	Colon Ca	Active	FOLFIRI	NA
Conatumumab	1b/2	Colon Ca	Active	panitumumab	NA

Abbreviations: NHL, non-Hodgkin's lymphoma, NSCLC, non-small-cell lung carcinoma, PR, partial response, and SO, stable disease.